Zimmer Biomet (NYSE:ZBH) Stock Gets Price Target Boost from Wells Fargo & Company

Zimmer Biomet (NYSE:ZBH) had its price objective upped by stock analysts at Wells Fargo & Company from $103.00 to $113.00 in a research note issued on Thursday, Benzinga reports. The brokerage presently has an “equal weight” rating on the medical equipment provider’s stock. Wells Fargo & Company‘s price target suggests a potential upside of 3.02% from the company’s previous close.

Several other equities analysts have also recently commented on ZBH. Sanford C. Bernstein upped their price target on Zimmer Biomet from $91.00 to $93.00 and gave the company a “market perform” rating in a report on Thursday, August 6th. Citigroup reissued a “neutral” rating on shares of Zimmer Biomet in a report on Monday, October 5th. Truist Financial upped their target price on Zimmer Biomet from $92.00 to $106.00 and gave the company a “hold” rating in a research note on Thursday, August 6th. Weiss Ratings raised Zimmer Biomet from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, September 14th. Finally, Royal Bank Of Canada lifted their price target on shares of Zimmer Biomet from $101.00 to $110.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. Seven equities research analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $106.89.

Zimmer Biomet Stock Performance

ZBH stock traded down $0.46 on Thursday, reaching $109.69. 364,791 shares of the company were exchanged, compared to its average volume of 2,250,515. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94. Zimmer Biomet has a 12 month low of $79.12 and a 12 month high of $112.54. The stock’s fifty day moving average price is $94.90 and its 200 day moving average price is $91.89. The firm has a market capitalization of $20.92 billion, a PE ratio of 26.64, a PEG ratio of 2.33 and a beta of 0.50.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The company had revenue of $2.06 billion for the quarter, compared to the consensus estimate of $2.04 billion. During the same quarter in the previous year, the firm posted $1.90 EPS. The business’s revenue was up 3.1% compared to the same quarter last year. On average, research analysts anticipate that Zimmer Biomet will post 8.54 EPS for the current fiscal year.

Insider Activity at Zimmer Biomet

In other news, insider Chad F. Phipps sold 3,000 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of $98.35, for a total value of $295,050.00. Following the transaction, the insider owned 65,231 shares of the company’s stock, valued at $6,415,468.85. This represents a 4.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Kevin R. Thornal sold 5,691 shares of Zimmer Biomet stock in a transaction on Friday, September 11th. The stock was sold at an average price of $92.95, for a total transaction of $528,978.45. Additional details regarding this sale are available in the official SEC disclosure. 1.28% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Zimmer Biomet

A number of large investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in Zimmer Biomet in the 2nd quarter valued at approximately $1,344,282,000. State Street Corp increased its position in Zimmer Biomet by 0.6% in the 2nd quarter. State Street Corp now owns 8,877,171 shares of the medical equipment provider’s stock valued at $766,343,000 after buying an additional 52,044 shares in the last quarter. Primecap Management Co. CA acquired a new position in Zimmer Biomet during the second quarter worth $328,578,000. Dimensional Fund Advisors LP grew its holdings in shares of Zimmer Biomet by 1.1% during the first quarter. Dimensional Fund Advisors LP now owns 2,224,163 shares of the medical equipment provider’s stock valued at $201,082,000 after buying an additional 24,208 shares during the last quarter. Finally, Bank of America Corp DE acquired a new stake in shares of Zimmer Biomet in the 2nd quarter worth about $187,480,000. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet News Summary

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Third-quarter sales were $2.063 billion, up 3.1% year over year (3.7% at constant currency), topping estimates of $2.04 billion. Adjusted diluted EPS of $1.90 also exceeded consensus, while the company raised its full-year 2026 financial guidance. These results and the improved outlook are key supports for the shares. Zimmer Biomet Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Hip and S.E.T. sales helped counter a challenging knee market. The CEO also said the company is not seeing a slowdown in orthopedic procedures, offering reassurance on underlying demand. Zimmer Biomet Q3 2026: How Diversification Offset a Weak Knee Quarter Zimmer Biomet CEO doesn’t see slowdown in ortho procedures
• Negative Sentiment: Reported diluted EPS fell 13.8% to $1.00, while adjusted EPS of $1.90 was unchanged from a year earlier. Knee weakness and margin pressure temper the positive sales and guidance news. Zimmer Biomet Q3 Profit Falls, Lifts FY26 Outlook

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.